27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. 5 key findings →
Design: meta-analysis Participants: 31,250 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Then, voxel-wise brainwide association analyses were used to identify gray matter volumes (GMVs) associated with social isolation and with loneliness. 5 key findings →
Design: cohort Participants: 462,619 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A healthy lifestyle as a composite score is associated with a substantially lower risk of Alzheimer's dementia. 5 key findings →
Design: meta-analysis Participants: 1,845 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This long-term follow-up of the SPRINT randomized trial tested whether intensively lowering systolic blood pressure (to below 120, vs. the standard target of below 140) reduces the risk of thinking problems in adults 50+ with hypertension. 4 key findings →
Design: RCT Participants: 9,361 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this study, we found that ePVS counts were not associated with cognitive dysfunction in the general population. 5 key findings →
Design: meta-analysis Participants: 3,575 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79, and 25.2% for 80-84. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among military veterans, mTBI is associated with 56% increased risk of PD, even after adjusting for demographics and medical/psychiatric comorbidities. 4 key findings →
Design: cohort study Participants: 325,870 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this prospective cohort study, higher consumption of UPF was associated with higher risk of dementia, whereas substituting unprocessed or minimally processed foods for UPF was associated with lower risk of dementia. 5 key findings →
Design: cohort Participants: 72,083 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. 5 key findings →
Design: cohort Participants: 358,862 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High cholesterol in late life was associated with decreased dementia risk, which is in contrast to previous studies suggesting high cholesterol in mid-life is a risk factor for later dementia. 5 key findings →
Design: longitudinal study Participants: 392 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Classification of evidence This study provides Class II evidence that specific dual-task training improves dual-task performance during walking under complex S3 conditions in geriatric patients with mild to moderate dementia. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In a study of nearly 190,000 older US military veterans, those who had experienced a traumatic brain injury were about 57% more likely to develop dementia over the next 9 years than veterans without a brain injury history. 4 key findings →
Design: cohort Participants: 188,764 Evidence: high
Full summary, score breakdown and related studies → Original source
Atrial fibrillation, hypertension, and angina were associated with a greater rate of decline and may represent modifiable risk factors for secondary prevention in Alzheimer disease. 3 key findings →
Design: longitudinal study Participants: 135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →
Design: cohort Participants: 322,358 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our data from a population-based study support the hypothesis that estrogen-replacement therapy is associated with a reduced prevalence of Alzheimer's disease in postmenopausal women. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
APOE ε4 carriage and older age were predictors of longitudinal Aβ accumulation within the Aβ- group but not the Aβ+ group. 5 key findings →
Design: longitudinal study Participants: 325 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 0.04). Replacing 1 serving per day of nuts and legumes for processed red meat was associated with a 19% lower risk of dementia (HR 0.81, 95% CI 0.75-0.86), 1.37 fewer years of cognitive aging (95% CI -2.49 to -0.25), and a 21% lower risk of SCD (RR 0.79, 95% CI 0.68-0.92). 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early age at surgical menopause was associated with cognitive decline and AD neuropathology. 4 key findings →
Design: longitudinal study Participants: 1,884 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Smoking cessation was associated with a sustained lower dementia risk and slower cognitive decline, comparable to never smokers and those without short-term risk increase. 5 key findings →
Design: cohort Participants: 32,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High intake of total, saturated, and trans fat and cholesterol and low intake of MUFA, PUFA, n-6 PUFA, and n-3 PUFA were not associated with increased risk of dementia or its subtypes. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Systematic review of the literature using the American Academy of Neurology's evidence-based methods. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher baseline body mass index (BMI) and slower declining BMI in late life are associated with a reduced risk of dementia, suggesting that low BMI or a faster decline in BMI in late life may be preclinical indicators of an underlying dementing illness, especially for those who were initially overweight or obese. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The findings support the cross-cultural use of a relatively inexpensive odor identification test as an early biomarker of cognitive decline and AD dementia. 1 key finding →
Participants: 1,037 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. 2 key findings →
Participants: 104 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To explore the nature of the olfactory dysfunction associated with Parkinson's disease (PD), 81 PD patients who scored well on a cognitive screening test were administered the 40-odorant University of Pennsylvania Smell Identification Test; 38 were additionally given a forced-choice phenylethyl alcohol odor detection threshold test. 2 key findings →
Design: longitudinal study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →